BACKGROUND: Although current performance measures recommend smoking cessation counseling at the time of acute myocardial infarction (AMI), the American College of Cardiology/American Heart Association guidelines recommend pharmacotherapy as well. The aim of this study was to describe the prevalence and correlates of smoking cessation pharmacotherapy in hospitalized patients with AMI. METHODS: In the 24-center TRIUMPH registry, 4,340 AMI patients underwent detailed interviews; and 1,631 reported smoking within 30 days of admission. Prescription of first-line smoking cessation medications at discharge was assessed by medical record review. All patient-related factors associated with smoking cessation treatment, based on literature review, were included in hierarchical modified log Poisson models. RESULTS: Only 14% (222/1,631) of AMI patients who smoked were prescribed smoking cessation medication at discharge. After multivariable adjustment for patient characteristics, there was significant variation across sites (range 0%-28%, median rate ratio 1.41, 95% CI 1.23-2.67). Independent factors associated with smoking cessation pharmacotherapy included older age (rate ratio 0.81 per 10-year increment, 95% CI 0.71-0.93), high school graduation (rate ratio 1.37, 95% CI 1.10-1.66), heavy cigarette usage (>20/d) (rate ratio 3.08, 95% CI 2.20-4.12), in-hospital revascularization (rate ratio 1.41, 95% CI 1.0-1.94), and instructions on smoking cessation (rate ratio 2.37, 95% CI 1.40-4.01). CONCLUSIONS: Smokers surviving an AMI are infrequently prescribed guideline-recommended smoking cessation treatments, and there is considerable variation across hospitals. Older, less educated, and lighter smokers are less likely to receive aggressive smoking cessation treatment. Novel strategies to augment current practice are needed. Published by Mosby, Inc.
BACKGROUND: Although current performance measures recommend smoking cessation counseling at the time of acute myocardial infarction (AMI), the American College of Cardiology/American Heart Association guidelines recommend pharmacotherapy as well. The aim of this study was to describe the prevalence and correlates of smoking cessation pharmacotherapy in hospitalized patients with AMI. METHODS: In the 24-center TRIUMPH registry, 4,340 AMI patients underwent detailed interviews; and 1,631 reported smoking within 30 days of admission. Prescription of first-line smoking cessation medications at discharge was assessed by medical record review. All patient-related factors associated with smoking cessation treatment, based on literature review, were included in hierarchical modified log Poisson models. RESULTS: Only 14% (222/1,631) of AMI patients who smoked were prescribed smoking cessation medication at discharge. After multivariable adjustment for patient characteristics, there was significant variation across sites (range 0%-28%, median rate ratio 1.41, 95% CI 1.23-2.67). Independent factors associated with smoking cessation pharmacotherapy included older age (rate ratio 0.81 per 10-year increment, 95% CI 0.71-0.93), high school graduation (rate ratio 1.37, 95% CI 1.10-1.66), heavy cigarette usage (>20/d) (rate ratio 3.08, 95% CI 2.20-4.12), in-hospital revascularization (rate ratio 1.41, 95% CI 1.0-1.94), and instructions on smoking cessation (rate ratio 2.37, 95% CI 1.40-4.01). CONCLUSIONS: Smokers surviving an AMI are infrequently prescribed guideline-recommended smoking cessation treatments, and there is considerable variation across hospitals. Older, less educated, and lighter smokers are less likely to receive aggressive smoking cessation treatment. Novel strategies to augment current practice are needed. Published by Mosby, Inc.
Authors: A M Joseph; S M Norman; L H Ferry; A V Prochazka; E C Westman; B G Steele; S E Sherman; M Cleveland; D O Antonuccio; D O Antonnucio; N Hartman; P G McGovern Journal: N Engl J Med Date: 1996-12-12 Impact factor: 91.245
Authors: Michael B Steinberg; Shelley Greenhaus; Amy C Schmelzer; Michelle T Bover; Jonathan Foulds; Donald R Hoover; Jeffrey L Carson Journal: Ann Intern Med Date: 2009-04-07 Impact factor: 25.391
Authors: William R Lewis; Eric D Peterson; Christopher P Cannon; Dennis M Super; Kenneth A LaBresh; Kathleen Quealy; Li Liang; Gregg C Fonarow Journal: Arch Intern Med Date: 2008-09-08
Authors: David Katz; Mark Vander Weg; Steve Fu; Allan Prochazka; Kathleen Grant; Lynne Buchanan; David Tinkelman; Heather Schacht Reisinger; John Brooks; Stephen L Hillis; Anne Joseph; Marita Titler Journal: Implement Sci Date: 2009-09-10 Impact factor: 7.327
Authors: David A Katz; Donna M Buchanan; Mark W Vander Weg; Babalola Faseru; Philip A Horwitz; Philip G Jones; John A Spertus Journal: Prev Med Date: 2018-10-11 Impact factor: 4.018
Authors: Jae-Sik Jang; Donna M Buchanan; Kensey L Gosch; Philip G Jones; Praneet K Sharma; Ali Shafiq; Anna Grodzinsky; Timothy J Fendler; Garth Graham; John A Spertus Journal: Circ Cardiovasc Interv Date: 2015-05 Impact factor: 6.546
Authors: A Benjamin Srivastava; Alex T Ramsey; Leslie D McIntosh; Thomas C Bailey; Sherri L Fisher; Louis Fox; Mario Castro; Yinjiao Ma; Timothy B Baker; Li-Shiun Chen; Laura J Bierut Journal: Nicotine Tob Res Date: 2019-04-17 Impact factor: 4.244